Epigenetic Control of Cancer Cell Dormancy and Awakening in Endocrine Therapy Resistance-Reference-Cited by-同舟云学术

Epigenetic Control of Cancer Cell Dormancy and Awakening in Endocrine Therapy Resistance

Published:2024-04-10 Issue:5 Volume:14 Page:704-706
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:

Author:

Llinas-Bertran Arnau¹^ORCID,Bellet-Ezquerra Meritxell²³^ORCID,Seoane Jose A.¹^ORCID

Affiliation:

1. 1Cancer Computational Biology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.

2. 2Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.

3. 3Breast Cancer Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.

Abstract

Summary: Rosano, Sofyali, Dhiman, and colleagues show that epigenetic-related changes occur in endocrine therapy (ET)-induced dormancy in estrogen receptor positive (ER+) breast cancer, as well as in its reawakening. Targeting these epigenetic changes blocks the entrance to dormancy and reduces the persister cancer cell population, enhancing the cytotoxic effects of ET in vitro. See related article by Rosano et al., p. 866 (9).

Publisher

American Association for Cancer Research (AACR)

Link

https://aacrjournals.org/cancerdiscovery/article-pdf/doi/10.1158/2159-8290.CD-24-0282/3441416/cd-24-0282.pdf

Reference9 articles.

1. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years;Pan;N Engl J Med,2017

2. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations;Sharma;Cell,2010

3. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance;Shaffer;Nature,2017

4. HDAC inhibitors induce LIFR expression and promote a dormancy phenotype in breast cancer;Clements;Oncogene,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Elevated GRHL2 Imparts Plasticity in ER-Positive Breast Cancer Cells;Cancers;2024-08-21